# Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

> **NCT01730404** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 55 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** CHF6001 DPI
- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01730404
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2017-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01730404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01730404, "Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01730404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*